Use of an 8¹3² Asymmetrical Factorial Design for the In Vitro Evaluation of Ondansetron Permeation Through Human Epidermis

References

• Llacer J. M., Gallardo V., Parera A., Ruiz M. A. Formation of ondansetron polymorphs. Int. J. Pharm. 1999; 177: 221–229
   PubMedGoogle Scholar
• Roila F., Favero D. A. Ondansetron clinical pharmacokinetics. Clin. Pharmacokinet. 1995; 29(2)95–109
   PubMed Web of Science ®Google Scholar
• Simpson K. H., Hicks F. M. Clinical pharmacokinetics of ondansetron. A review. J. Pharm. Pharmacol. 1996; 48: 774–781
   PubMed Web of Science ®Google Scholar
• Cothhup P. V., Felgate C. C., Palmer J. L., Scully N. L. Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly. J. Pharm. Sci. 1991; 80(9)868–871
   PubMed Web of Science ®Google Scholar
• Llacer J. M., Ruiz M. A., Parera A., Gallardo V. Adsortion–desorption of ondansetron on latex particles. Drug Dev. Ind. Pharm. 2000; 26(3)237–242
   PubMed Web of Science ®Google Scholar
• www.fda.gov/medwatch/safety/2000/dec00.htm, (accessed July 2002)
   Google Scholar
• Anderson P. O., Knoben J. E., Troutman W. G. Handbook of Clinical Drug Data. Appleton & Lange, Connecticut 1999, 519 pp.
   Google Scholar
• Micromedex. Thomson Healthcare. Thomson Healthcare, 2001; Vol. 109, 3rd Quarter
   Google Scholar
• Pfister W. R., Hsieh D. S.T. Permeation enhancers compatible with transdermal drug delivery systems Part I: selection and formulation considerations. Pharm. Technol. 1990; 14(9)132–139
   Google Scholar
• The Merck Index on CD‐ROM, v. 12:2. Merck & Co., Whitehouse State, NJ 1997
   Google Scholar
• The United States Pharmacopeia 24. United States Pharmacopeial Convention, Rockville, MD 2000; 1218–1220
   Google Scholar
• Takahashi K., Rytting J. H. Approach to improve permeation of ondansetron across shed snake skin as a model membrane. J. Pharm. Pharmacol. 2001; 53: 789–794
   PubMed Web of Science ®Google Scholar
• Giannakou S. A., Dallas P. P., Rekkas D. M., Choulis N. H. Development and in vitro evaluation of nimodipine transdermal formulations using factorial design. Pharm. Dev. Technol. 1998; 3(4)517–525
   PubMedGoogle Scholar
• Klingman A. M., Christophers E. Preparation of isolated sheets of human stratum corneum. Arch. Dermatol. 1963; 88: 702–709
   PubMed Web of Science ®Google Scholar
• Bolton S. Pharmaceutical Statistics. Marcel Dekker, Inc., New York 1984; 258–280
   Google Scholar
• Montgomery D. C. Introduction to Statistical Quality Control3rd Ed. John Wiley & Sons, Inc., New York 1997; 512–571
   Google Scholar
• Montgomery D. C. Design and Analysis of Experiments4th Ed. John Wiley & Sons, Inc., New York 1997; 228–280
   Google Scholar
• Lewis G. A., Mathieu D., Phan‐Tan‐Luu R. Pharmaceutical Experimental Design. Marcel Dekker, Inc., New York 1999; 23–76
   Google Scholar
• Voinovich D., Campisi B., Moneghini M., Vincezi C., Phan‐Tan‐Luu R. Screeening of high shear mixer melt granulation process variables using an asymmetrical factorial design. Int. J. Pharm. 1999; 190: 73–81
   PubMed Web of Science ®Google Scholar
• El‐Kattan A. F., Asbill C. S., Kim N., Michniak B. B. The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities. Int. J. Pharm. 2001; 215: 229–240
   PubMed Web of Science ®Google Scholar
• Walters K. A., Hadgraft J. Pharmaceutical Skin Penetration Enhancement. Marcel Dekker, Inc., New York 1993
   Google Scholar
• Gwak H. S., Chun I. K. Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin. Int. J. Pharm. 2002; 236: 57–64
   PubMed Web of Science ®Google Scholar
• Barry B. W. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur. J. Pharm. Sci. 2001; 14: 101–114
   PubMed Web of Science ®Google Scholar
• Barry B. W. Lipid‐protein‐partitioning theory of skin penetration enhancement. J. Control. Release 1991; 15: 237–248
   Web of Science ®Google Scholar
• Shin S. C., Kim J., Yoon M. K., Oh I. J., Choi J. S. Transdermal delivery of triprolidine using TPX polymer membrane. Int. J. Pharm. 2002; 235: 141–147
   PubMed Web of Science ®Google Scholar
• Monti D., Giannelli R., Chetoni P., Burgalassi S. Comparison of the effect of ultrasound and of chemical enhancers on transdermal permeation of caffeine and morphine through hairless mouse skin in vitro. Int. J. Pharm. 2001; 229: 131–137
   PubMed Web of Science ®Google Scholar
• Gabiga H., Cal K., Janicki S. Effect of penetration enhancers on isosorbide dinitrate penetration through rat skin from a transdermal therapeutic system. Int. J. Pharm. 2000; 199: 1–6
   PubMed Web of Science ®Google Scholar
• Francoeur M. L., Golden G. M., Potts R. O. Oleic acid: its effect on the stratum corneum in relation to (trans)dermal drug delivery. Pharm. Res. 1990; 7: 621–627
   PubMed Web of Science ®Google Scholar
• Walker M., Hadgraft J. Oleic acid—a membrane fluidizer or fluid within the membrane?. Int. J. Pharm. 1991; 71: R1–R4
   Google Scholar
• Kanikkannan N., Kandimalla K., Singh M. Structure–activity relationship of chemical penetration enhancers in transdermal drug delivery. Curr. Med. Chem. 2000; 7: 593–608
   PubMed Web of Science ®Google Scholar
• Andega S., Kanikkannan N., Singh M. Comparison of the effect of fatty alcohols on the permeation of melatonin between porcine and human skin. J. Control. Release 2001; 77: 17–25
   PubMed Web of Science ®Google Scholar
• Hadgraft J., Williams D. C., Allan G. K. A. Walters, J. HadgraftAzone: mechanisms of action and clinical effect. Pharmaceutical Skin Penetration Enhancement, . Marcel Dekker, Inc., New York 1993; 175–197
   Google Scholar
• Bach M., Lippold B. C. Percutaneous penetration enhancement and its quantification. Eur. J. Pharm. Biopharm. 1998; 46: 1–13
   PubMedGoogle Scholar
• Cleary G. W. Transdermal drug delivery. Cosmet. Toiletries 1991; 106: 97–109
   Google Scholar